OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma
Open Access
- 29 October 2012
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 93 (1) , 8-19
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinomaEuropean Journal of Cancer, 2011
- Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantationBlood, 2010
- Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenibWorld Journal of Hepatology, 2010
- Regulation of OPA1-mediated mitochondrial fusion by leucine zipper/EF-hand-containing transmembrane protein-1 plays a role in apoptosisCellular Signalling, 2009
- The Multikinase Inhibitor Sorafenib Potentiates TRAIL Lethality in Human Leukemia Cells in Association with Mcl-1 and cFLIPL Down-regulationCancer Research, 2007
- The ability of sorafenib to inhibit oncogenic PDGFR and FLT3 mutants and overcome resistance to other small molecule inhibitorsHaematologica, 2007
- The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma CellsCancer Research, 2006
- Arsenic trioxide (As2O3) induces apoptosis through activation of Bax in hematopoietic cellsOncogene, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Fusion, Fragmentation, and Fission of MitochondriaBiochemistry (Moscow), 2003